anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Lithium induces nephrogenic diabetes insipidus (NDI) and microcystic chronic kidney disease (CKD). As previous clinical studies suggest that NDI is dose-dependent and CKD is time-dependent, we investigated the effect of low exposition to lithium in a long-term experimental rat model. Rats were fed with a normal diet (control group), with the addition of lithium (Li+ group), or with lithium and amiloride (Li+/Ami group) for 6 months, allowing obtaining low plasma lithium concentrations (0.25 ± 0.06 and 0.43 ± 0.16 mmol/L, respectively). Exposition to low concentrations of plasma lithium levels prevented NDI but not microcystic dilations of kidney tubules, which were identified as collecting ducts (CDs) on immunofluorescent staining. Both hypertrophy, characterized by an increase in the ratio of nuclei per tubular area, and microcystic dilations were observed. The ratio between principal cells and intercalated cells was higher in microcystic than in hypertrophied tubules. There was no correlation between AQP2 messenger RNA levels and cellular remodeling of the CD. Additional amiloride treatment in the Li+/Ami group did not allow consistent morphometric and cellular composition changes compared to the Li+ group. Low exposition to lithium prevented overt NDI but not microcystic dilations of the CD, with differential cellular composition in hypertrophied and microcystic CDs, suggesting different underlying cellular mechanisms.
Oral contraceptives have been shown to cause a decrease in glucose tolerance in a significant percentage of users (17). This effect has been shown to be directly related to estrogen dose (65). In general, progestogens increase insulin secretion and create insulin resistance, this effect varying with different progestational agents (17,66). In the nondiabetic woman, oral contraceptives appear to have no effect on fasting blood glucose (67). Because of these demonstrated effects, prediabetic and diabetic women should be carefully monitored while taking oral contraceptives.

A small proportion of women will have persistent hypertriglyceridemia while on the pill. As discussed earlier (see WARNINGS 1.a. and 1.d.), changes in serum triglycerides and lipoprotein levels have been reported in oral contraceptive users.
BACKGROUND: Both dengue and Leptospira infections are endemic to tropical and subtropical regions, with their prevalence increasing in recent decades. Coinfection with these pathogens presents significant diagnostic challenges for clinicians due to overlapping clinical manifestations and laboratory findings. This case report aims to elucidate two clinical scenarios where the coinfection of dengue and leptospirosis complicates the disease course, creating a diagnostic conundrum.
CASE PRESENTATION: We present the clinical scenarios of two Bangladeshi males, aged 25 and 35 years, who were admitted to our hospital with acute febrile illness. The first patient exhibited hepatic and renal involvement, while the second presented with symptoms initially suggestive of meningoencephalitis. Both cases were initially managed under the presumption of dengue infection based on positive serology. However, further evaluation revealed coinfection with Leptospira, complicating the disease course. Both patients received appropriate treatment for dengue and antibacterial therapy for leptospirosis, ultimately resulting in their recovery.
CONCLUSION: These case scenarios underscore the critical importance for clinicians in regions where dengue and Leptospira are endemic to consider both diseases when evaluating patients presenting with acute febrile illness.
The present document relates to an image data processing method for processing imaging data from different imaging systems, providing a harmonized three- dimensional data set for enabling analysis independent of the image system. The method comprises: obtaining the imaging data Which comprises a array of input voxels, and segmenting the data to provide at least one two-dimensional data slice. The method also comprises reconstructing a three-dimensional data set from the data slices. Prior to segmenting, a step of preprocessing is performed, which includes image normalization of the imaging data. This includes at least a transforming or processing of the imaging data for mapping the imaging data onto an image data standard. The document also descries a method of training a machine learning data processing model and an image processing system. The methods and system may be applied to perform harmonized classification and/or radiomics for a plurality of systems.
The invention discloses a probiotic fermented lily composition for improving lung health, and a preparation method and application thereof, and belongs to the technical field of biology. The fermentation lactobacillus mucilaginosus preservation number: cctccc No. M20231858. The fermentation composition is a fermentation composition of lactobacillus mucilaginosus GR-3 and lily bulbs separated from slurry water. The fermentation of lactobacillus mucilaginosus GR-3 increases the free of natural active compounds in lily bulbs by fermentation and improves bioavailability. The free natural product has stronger in vitro free radical scavenging ability. The fermentation composition is effective in limiting inhaled carbon black nanoparticle deposition, reducing lung tissue damage and proinflammatory cytokines, restoring beneficial microbiota in the lung, and alleviating inflammation. The fermentation composition is used for improving lung health, and has wide application prospects in the fields of foods, health products, medicines and the like.
The invention is a kind of quick-released tablet of shenshuai fruit elements and the manufacturing method. The tablet contains 10-30 % shenshuai fruit element extraction material, 2-5 % sputtering agent, 1.5-3%, the other is filter. The sputtering agent is cross-linked sodium cellulose glycolate, sodium carboxy methyl starch or the compound of them. The additive includes lubricant, flow aid, deodorizing agent. The filler is the compound of alditol and cellulose. The method used polyketone as adhesive, used alcohol or the fixed liquid of alcohol and water as humectant. The sputtering agent uses inner adding method or outer adding method, wet process to produce particles. The character of the invention lies in fast dilution, the medicine can be dissolved entirely in then minutes, it needn't sugar-coat, the troche has good taste, it has no obvious bitterness.
The invention discloses preparation of a novel siRNA nano delivery system and application thereof in prostatic cancer. The preparation method is that siRNA targeting skp2 and natural flavonoid medicine quercetin are assembled to form nano particles through hydrogen bonds, pi-pi action and hydrophobic action. The invention can carry quercetin and siRNA into prostate tumor cells simultaneously, and the quercetin and siRNA synergistically promote the down regulation of skp2 protein to inhibit the proliferation and migration of prostate cancer cells. According to the invention, through molecular level and in vitro activity evaluation, the system is proved to be superior to the system for simultaneously conveying each single component, the anticancer activity of the system can be obviously improved, and a clear synergistic treatment effect is achieved. The invention has definite anti-tumor effect, and the used materials have anti-tumor effect, good biocompatibility, biodegradability and nontoxicity. The preparation process is simple and easy to operate.
We will cover patients incision with regular gauze bandages. These are the bandages that patients normally get after spinal fusion surgery. They will be left on for 72 hours.
As per preceding commendation, Modified Oswestry Low Back Pain Scale will be translated into Urdu language from its English version and adapted culturally in Pakistan. 100 individuals will be selected on the basis of convenience sampling with clinical characteristics. The patient will answer the questionnaire package that included the Urdu version Modified Oswestry Low Back Pain Scale, Quebec back pain disability scale, Roland-Morris disability questionnaire and Visual analogue scale on the same day, with a 30-minute delay between the first and second application. Observer-1 will be conducting a third assessment after 7 days for intra-observer evaluation. Statistical Package of Social Sciences Version 24 will be used to enter and evaluate the data. Internal consistency will be measured using the Cronbach alpha value. To evaluated test-retest reliability, an intraclass correlation coefficient will be employed. The Modified Oswestry Low Back Pain Scale will be evaluated for content validity, construct validity, criterion validity, and responsiveness.
OBJECTIVES: The Fluconazole pharmacokinetic-pharmacodynamic relationship was investigated in a few clinical settings and only limited studies regarding burned patients are available. Thus, the authors aimed to investigate fluconazole pharmacokinetics changes and its impact on antifungal therapy coverage against dose-dependent Candida spp. applying the PK/PD approach in critically ill severely burned patients.
METHODS: Fluconazole was administered as a one-hour intravenous infusion of 200 mg q12h. Doses were increased according to the coverage based on the PK/PD approach. Blood samples were collected at the end of the infusion (1st hour), two hours after (3rd hour), and before the next dose (12th or 24th hour). Serum concentrations were obtained by HPLC-UV. Pharmacokinetic parameters were estimated by noncompartmental analysis and compared with data described in healthy subjects. The effectiveness predictive index was based on the AUCss0-24h/MIC ratio, with a target above 25.
RESULTS: Every pharmacokinetic parameter was reduced throughout all three sets of the study. Compared to healthy subjects, the volume of distribution was decreased about 3‒7 times, biological half-life was 2‒3 times shorter and total body clearance was slightly altered but statistically significant. Both half-life and total body clearance were correlated to the volume of distribution. Consequently, an increase in fluconazole daily dose was necessary to improve empiric coverage.
CONCLUSIONS: Fluconazole pharmacokinetics is altered in critically ill severely burned patients, mainly related to the volume of distribution. Doses higher than usual may be necessary to reach the PK/PD target and guarantee antifungal coverage against dose-dependent Candida spp. up to MIC 32 mg/L.
Based on novel recognition to cough, the present invention provides a medicine for treating cough and a use method thereof. The present invention uses an effective medicinal prescription with traditional Chinese medicines of westen treatment. By means of a high technology, the medicine for treating cough is prepared from the traditional Chinese medicines and western medicines which are made into the dosage forms of tablets, capsules, granules and syrup or the dosage forms of two colors. A formula (1) is suitable for cough in daytime and lime is used as a chief medicine. A formula (2) is suitable for cough at night and Chinese angelica root is used as a chief medicine. The formula (1) and the formula (2) are suitable for being as a medicine for treating cough in daytime and at night, particularly have peculiar effect on cough symptoms at night. The medicine for treating cough is refined, thin and small. The present invention has the advantages of convenient administration and portability and overcomes the defects that a compound preparation of the traditional Chinese medicines and western medicines is thick, large and black. For the time of medication, the medicine for treating cough can treat cough in time. The present invention also has the advantages of advanced preparation technology, extensive and new medicine sources, low price, wide medication range for various kinds of cough and large markets. The present invention is suitable for the industrial production of each pharmaceutical factory.
This is a prospective, observational study to measure and collect and physical parameters from females at least 20 years of age in the labor room. Collection of measurements and physical parameters will begin when the subject enrolls in the study. Besides, ECG and SpO2 will be recorded continuously until the end of the study period. In addition, uterus contraction cycle and fetal heart beat will be recorded during the study period based on standard of care in the labor room. Pain will be recorded on a visual analogue scale (VAS) at baseline and when the caregiver perceives that there is a change in the subject's pain status until the end of the study period. The time of each assessment of pain on VAS should be recorded. Subjects will be withdrawn from the study if they have a cesarean section or any complication during labor in the opinion of the investigator. Subject participation in the study will end when eight hours have elapsed since baseline, the subject leaves the labor room or the subject delivers the baby.
Pharmaceutical compositions for the treatment of hypertension comprise as active ingredient or ingredients 9-aminodecalin derivatives of formula <FORM:0821077/VI/1> wherein R1 is an hydrogen atom or an alkyl, alkenyl or aralkyl radical and R2 is an hydrogen atom or an alkyl radical, and/or the non-toxic, pharmaceutically-acceptable acid addition salts thereof together with non-toxic pharmaceutical excipients.  Specified derivatives are 9-methylamino-, 9-ethylamino-, 9-allylamino-, 9-dimethylamino- and 9-N-methyl-N-ethyl aminodecalin and 9-benzylaminodecalin. Suitable salts are those of common inorganic acids, e.g. hydrochloric acid, common organic acids, e.g. acetic, cinnamic, salicylic acids, hydroxy and polyhydroxy acids, acids bearing lipophilic residues, e.g. oleic and stearic acids.  The composition may take the form of sterile aqueous solutions, suspensions or emulsions or sterile non-aqueous solutions or suspensions which may contain from 0.05 to 20% by weight of the active ingredient.  Suitable vehicles for the non-aqueous solutions and suspensions are propylene glycol, polyethylene glycol, vegetable oils, e.g. arachis, olive and peanut oil and oil-like injectable organic esters, e.g. dibutyl succinate. Sterilization may be accomplished by aseptic formulation, Seitz filtration, irradiation, incorporation in the composition of sterilizing agents, or heat treatment.  The composition may take the form of sterile powders suitable for admixture with sterile aqueous media to provide sterile aqueous solutions, suspensions or emulsions suitable for parenteral administration and also tablets, pills, dispersible powders and granules, e.g. soft or hard gelatine capsules.  When in tablet form, the active ingredient which may be absorbed on an ion-exchange resin may be present in amount from 5 to 50 parts by weight to 100 parts by weight of the composition.  The composition may also take the form of a semi-solid or liquid formulation, e.g. emulsions, suspensions, syrups, or elixirs, a form suitable for admixture with foodstuffs, or may be formulated with feedstuffs. Other known therapeutic agents may also be present in the compositions for oral use, e.g. reserpine, extracts of Rauwolfia, Serpentina, meprobamate or aspirin.  Other materials which may be present are calcium carbonate, maize starch, magnesium and aluminium stearate, cellulose acetate phthalate, cellulose diethyl phthalate, sodium carboxymethyl cellulose, chlorocresol, sorbitan mono-oleate, polyoxyethylene sorbitan mono - oleate, nor - dihydroguariaretic acid, methyl and propyl-p-hydroxy benzoate, refined soya bean lecithin, polyvinyl pyrrolidone, propylene glycol, lactose, sodium saccharin, sulphonated cross-linked polystyrene resin in hydrogen form, and ethanol.
PURPOSE: To obtain the subject low-viscosity contrast medium consisting mainly of barium sulfate, excellent in redispersibility even after precipitated. CONSTITUTION: This contrast medium is obtained by incorporating a barium sulfate suspension with a swellable additive such as an insoluble disintegrant (a physiologically permissible and water-insoluble high-molecular compound, e.g. carboxymethylcellulose). It is appropriate that the barium sulfate concentration of the suspension be 0.5-6.0wt.% and the particle diameter thereof 0.5-2μm. The water-insoluble high-molecular compound accounts for 0.2-3wt.% of the suspension. The contrast medium also contains a conventional antiseptic, dissolution auxiliary, defoaming agent, sweetener, flavor, perfume, etc., according as appropriate.  When the contrast medium is homogeneously agitated and then allowed to stand, the barium sulfate and additive freely or flocaulatingly precipitate, thus resulting in mixed precipitation at the bottom of a vessel or forming a sediment layer (soft cake) of the barium sulfate in a layer on the additive. Therefore, even after being left to stand for a long time, this contrast medium exhibits excellent redispersibility merely by simple handy shaking when to be used.
Participants will receive oral dosing of NNC0487-0111 and gradually will escalate from dose 1 to dose 2. The oral NNC0487-0111 treatment will be followed by s.c. NNC0487-0111 treatment with dose escalating from dose 3 to dose 4.
The invention relates to a non-aqueous taxane nano dispersion preparation and a using method thereof. Specifically, non-aqueous, ethanol-free taxane nanodispersion formulations are provided. The nanodispersion formulations of embodiments of the invention comprise a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of the non-ionic surfactant is greater than or equal to the amount by weight of the non-aqueous solvent. Also provided are non-aqueous, ethanol-free docetaxel nanodispersion formulations. The nanodispersion formulations of embodiments of the invention comprise docetaxel, an oil, a non-ionic surfactant, a non-aqueous solvent, an organic acid dissolved in the non-aqueous solvent and substantially free of any conjugate base. Also provided are methods of using the nanodispersion formulations, and kits comprising the nanodispersion formulations.
PURPOSE:To obtain a cosmetic, excellent in heat resistance, light fastness and skin stability, good in color tone and coloring without any feeling of roughness, etc., having excellent touch without any irritation by blending a silver hydrosol which is a dispersion prepared by dispersing silver in an ultrafine particulate state in water. CONSTITUTION:A cosmetic containing a silver hydrosol prepared by treating, e.g. an aqueous solution of a silver salt such as silver nitrate as a raw material with a reducing agent of an aqueous solution such as sodium boron hydride, sodium citrate or ascorbic acid. The cosmetic is excellent in heat resistance, light fastness and skin stability. The aforementioned cosmetic is excellent in color tone and coloring properties and good in preservation stability without any skin irritation, carcinogenicity, etc., with high safety for the skin. The above-mentioned cosmetic can be applied to lotions, milky lotions, creams, packs, soaps, etc.
Subjects will receive regimens 50 mcg, 100 mcg and 150 mcg in a sequential manner in consecutive treatment periods. Subjects who have tolerated the IMP in all prior regimens will continue in the study to receive each subsequent dose.
Disclosed is an antigen-binding fragment (Fab) or an aptamer that recognises an unidentified epitope in an extracellular part of CD9, wherein the Fab or the aptamer bind directly to the extracellular part of the CD9 at a similar location. Specifically, the Fab is a fragment of a monoclonal antibody and has a size of approximately 40-60 kDa, 45-55 kDa, 48-52 kDa or 50 kDa, and wherein the monoclonal antibody is at least one of an anti-human CD9 and an anti-CD9. Also disclosed is a biological molecular assay that recognises an epitope in an extracellular part of a CD9. The biological molecular assay includes use of an antigen-binding fragment (Fab) and an aptamer. The Fab and the aptamer bind directly in operation to the extracellular part of the CD9 at similar locations. The biological molecular assay is implement using a pharmaceutical composition. The pharmaceutical composition comprises pharmaceutically acceptable excipients adjuvants and carriers. Use of the Fab fragments in treatment of cancer or infections or diseases is further claimed.
The invention discloses an artificial synthetic active peptide for promoting cartilage repair, the amino acid sequence of which is shown in SEQ ID NO:1, the active peptide is composed of 296 amino acids and has a molecular weight of 33.95kDa. The active peptide forms a secondary structure with 6 alpha helices and 7 beta sheets. The active peptide can be synthesized by a stepwise condensation directional active peptide synthesis method. The synthetic active peptide has the capabilities of promoting chondroblast differentiation, delaying cartilage injury and promoting articular surface cartilage repair, is soluble in water, and has good biological safety. The cartilage damage on the joint surface of the knee osteoarthritis of the mice can be delayed by the method of injecting the joint cavity. The invention also discloses a preparation method of the artificially synthesized active peptide, which has mature and stable process and is easy to control.
The present invention provides a method for the treatment of viral-induced tumors in mammals, more specifically, human warts. The method uses alpha- and beta-santalols, or mixtures or derivatives thereof, to prepare medicaments for the treatment of viral-induced tumors i.e., warts caused by the human papillomavirus (HPV) in humans. The method of the invention comprises the topical administration of alpha- and beta-santalols, or mixtures or derivatives thereof, in a composition derived therefrom, to the human epidermis, as needed. The present invention is also concerned with a unique antiviral composition useful for topical application. The antiviral composition according to this invention is also effective against other DNA viruses such as the DNA pox virus that causes Molluscum contagiosum and may be effective against other DNA viruses such as AIDS virus and RNA viruses. The alpha- and beta-santalols composition, or mixtures or derivatives thereof, may also be effective in the treatment of genital warts and HPV of the genital tract and in the treatment of cancer of the skin and cervix. The alpha- and beta-santalols, or mixtures or derivatives thereof, may also be effective in the prevention of dryness of the skin, rashes and flakiness associated with seborrheic dermatitis, psoriasis and allergic or eczematous rashes of the skin. The alpha- and beta-santalols, or mixtures or derivatives thereof, may also be effective in the treatment of acne lesions of the face and the body and in the eradication of pustular acne lesions caused by staphylococcal acne and streptococcal bacterial infections.
The present invention provides a modified formula to make a hydrophilic foam. In some embodiments this modified formula adds a filler which causes the foam to become less absorptive, which has the benefit of making available to the skin more makeup or other products, while also providing a superior esthetic application of makeup on the skin. In other embodiments the modified formula makes the hydrophilic foam easier to clean and reduces the staining propensity of the foam. In other embodiments the modified formula uses an additive to the properties or usability of the foam in some way. Providing the filler and additive can be done in combination or separately depending on the desired benefits or properties of the foam. In some embodiments the foam is fashioned into a shape suitable for makeup application.